FAAIZA ARSHAD: Open Payments
NPI 1144887001 · HAYTI, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 38 payments from 11 companies in 2025. Trend: 2023 $695 · 2024 $452 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $307 |
| Otsuka America Pharmaceutical, Inc. | 6 | $139 |
| Lundbeck LLC | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Amgen Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: ARISTADA, REXULTI, COBENFY, GEMTESA, OTEZLA, FANAPT, FARXIGA, UZEDY.
Industry payments across MO — which companies pay providers there.
